MetrionAIIntelligence

Sign in Register

Home Watchlist Market News High Impact News Market Movers Screener Portfolio Calculators Heatmap Compare Calendars Crypto Forex Macro Maps

Research Tools

Financial Analysis Analyst Estimates Insider Trading Market Guide Trading Ideas Charts

Financial Analysis

Highlights Income Statement Balance Sheet Cash Flow Multiples Profitability

Loading market dashboard

My Watchlist

Sign in to track securities

Create an account to keep a persistent watchlist.

Home High Impact News Market Movers

Loading stock research

MMTec, Inc.

MTC

TechnologyNASDAQCN

Sign in to save

$3.50

-$0.49 (-12.28%)

Overview Financials Analysis Valuation Thesis Ownership Compare AI Report News

Loading disclosure news

MTC News

News and disclosures filtered by period, publisher, and event group.

1 / 1

Filter options

Period

From

To

Company only

Official only

Event search

Event group

Company announcementsFinancial reportsProspectus, capital raise, listingProfit distribution and paymentsPurchase offersLegal proceedingsTrading and market makerCompany detailsManagementSecurity termsCapital and holdersBoard decisions and meetingsInterested-party transactions

Results

Select a headline to open the full news page in the app.

Jun 6, 2026, 3:00 PMgurufocus.comMTC

Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and i

Company announcements

Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demo